Pharmaceuticals Global On demand · 24-48h

Global Antipyretic and Analgesic Drugs Market Strategic Research Report

Global Antipyretic and Analgesic Drugs Market Strategic Rese…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Antipyretic and Analgesic Drugs Market
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Paracetamol, Aspirin, Ibuprofen, Naproxen, Diclofenac, Oxapzin, Dexibuprofen, Anagen, Others

By Application: Aldult, Child

Key Players: Xinhua Pharmaceutical Company Limited, Mallinckrodt Pharmaceuticals, Jiheng Pharmaceutical Co., Ltd, Lu'an Pharmaceutical Co., Ltd., BASF, Seqens, IOL, Granules India, Wuyao Pharmaceutical Co., Ltd, Biocause Heilen Pharmaceutical Co., Ltd, Kangle Pharmaceutical CO., LTD, Fengyuan Pharmaceutical Co., Ltd., Haisen Pharmaceutical Co., Ltd, Jingye Medical Technology Co., Ltd, Liaoyuan Baikang Pharmaceutical Co., Ltd

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2024 · forecast to 2032
Length: 129 pages

Overview

Scope of the Report

Antipyretic and analgesic drugs are drugs that can restore the body temperature of patients with fever to normal, but have no effect on normal body temperature. These drugs also have moderate analgesic effects, but their intensity is not as strong as morphine and its synthetic substitutes. Commonly used antipyretic and analgesic drugs can be divided into salicylates, anilines, and pyrazolones based on their chemical structure. Except for anilines, all of these drugs have anti-rheumatic effects and can also treat rheumatism and rheumatoid arthritis. This report covers the market for active pharmaceutical ingredients (APIs) for antipyretic and analgesic drugs. In 2024, global Antipyretic and analgesic drugs production reached approximately Antipyretic and analgesic drugs 360.79 K MT, with an average global market price of around US$ 42.01 per kg.

China and India are two major producers of antipyretic and analgesic drugs, accounting for 51.32% and 18.42% of the market share, respectively, in 2024. China is expected to maintain the fastest growth rate in the coming years, with its share projected to reach 54.06% by 2031. China has sufficient production capacity for antipyretic and analgesic drugs and is actively expanding into the international market. Its global share is expected to gradually increase by 2031. In terms of product type, paracetamol holds a significant position, with a projected share of 42.16% by 2031. At the same time, in terms of application, the share of adults in 2024 will be approximately 75.37%, and the CAGR in the next few years will be approximately 2.49%.

This report presents a comprehensive overview of the global Antipyretic and Analgesic Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Paracetamol
  • Aspirin
  • Ibuprofen
  • Naproxen
  • Diclofenac
  • Oxapzin
  • Dexibuprofen
  • Anagen
  • Others

Segment by Application

  • Aldult
  • Child

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Antipyretic and Analgesic Drugs market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Aldult, Child evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type
ParacetamolAspirinIbuprofenNaproxenDiclofenacOxapzinDexibuprofenAnagenOthers
By Application
AldultChild

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Paracetamol
  • 3.1.3 Aspirin
  • 3.1.4 Ibuprofen
  • 3.1.5 Naproxen
  • 3.1.6 Diclofenac
  • 3.1.7 Oxapzin
  • 3.1.8 Dexibuprofen
  • 3.1.9 Anagen
  • 3.1.10 Others
  • 3.1.11 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Aldult
  • 4.1.3 Child
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Xinhua Pharmaceutical Company Limited
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Mallinckrodt Pharmaceuticals
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Jiheng Pharmaceutical Co., Ltd
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Lu'an Pharmaceutical Co., Ltd.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 BASF
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Seqens
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 IOL
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Granules India
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Wuyao Pharmaceutical Co., Ltd
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Biocause Heilen Pharmaceutical Co., Ltd
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Kangle Pharmaceutical CO., LTD
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Fengyuan Pharmaceutical Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Haisen Pharmaceutical Co., Ltd
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Jingye Medical Technology Co., Ltd
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Liaoyuan Baikang Pharmaceutical Co., Ltd
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is Antipyretic and Analgesic Drugs?
China and India are two major producers of antipyretic and analgesic drugs, accounting for 51.32% and 18.42% of the market share, respectively, in 2024. China is expected to maintain the fastest growth rate in the coming years, with its share projected to reach 54.06% by 2031. China has sufficient production capacity for antipyretic and analgesic drugs and is actively expanding into the international market.
What are the main segments of the Antipyretic and Analgesic Drugs market by type?
By type, the market is segmented into Paracetamol, Aspirin, Ibuprofen, Naproxen, Diclofenac, Oxapzin, Dexibuprofen and Anagen (and 1 more).
Which applications drive demand in the Antipyretic and Analgesic Drugs market?
Key applications covered include Aldult and Child.
Who are the key players in the Antipyretic and Analgesic Drugs market?
Key players profiled include Xinhua Pharmaceutical Company Limited, Mallinckrodt Pharmaceuticals, Jiheng Pharmaceutical Co., Lu'an Pharmaceutical Co., BASF, Seqens, IOL and Granules India, among 15 companies covered in total.
Which regions and countries are covered for Antipyretic and Analgesic Drugs?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Antipyretic and Analgesic Drugs market report?
The report is intended for manufacturers and solution providers, distributors and end users in Aldult and Child, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Antipyretic and Analgesic Drugs market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.